{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:10:21Z","timestamp":1767006621041,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.beha.2022.101378","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T01:00:38Z","timestamp":1661302838000},"page":"101378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach"],"prefix":"10.1016","volume":"35","author":[{"given":"Alexandros","family":"Rampotas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-9829","authenticated-orcid":false,"given":"Rupen","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2022.101378_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world Health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.beha.2022.101378_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2022.101378_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.beha.2022.101378_bib4","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2022.101378_bib5","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.beha.2022.101378_bib6","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2022.101378_bib7","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","article-title":"Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) \u2013 a clinicopathological study","volume":"13","author":"Thiele","year":"1999","journal-title":"Leukemia"},{"volume":"vol. 2","first-page":"439","year":"2008","key":"10.1016\/j.beha.2022.101378_bib8"},{"issue":"2","key":"10.1016\/j.beha.2022.101378_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","article-title":"Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter","volume":"27","author":"Barosi","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.beha.2022.101378_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035631","article-title":"Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis","volume":"7","author":"Barosi","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.beha.2022.101378_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2022.101378_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2022.101378_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12986","article-title":"Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia","volume":"167","author":"Harrison","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2022.101378_bib14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","article-title":"Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria","volume":"30","author":"Gisslinger","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2022.101378_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2022.101378_bib16","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2020002230","article-title":"Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients","volume":"4","author":"Sirinukunwattana","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2022.101378_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2022.101378_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant'Antonio","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2022.101378_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bjh.18087","article-title":"How I manage myeloproliferative neoplasm-unclassifiable: practical approaches for 2022 and beyond","volume":"197","author":"McLornan","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2022.101378_bib20","article-title":"Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): an international survey of contemporary practice","volume":"70","author":"Hargreaves","year":"2022","journal-title":"Curr Res Transl Med"},{"issue":"10","key":"10.1016\/j.beha.2022.101378_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-020-00368-1","article-title":"A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis","volume":"10","author":"Carobbio","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.beha.2022.101378_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.beha.2022.101378_bib23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","article-title":"In utero origin of myelofibrosis presenting in adult monozygotic twins","volume":"28","author":"Sousos","year":"2022","journal-title":"Nat Med"},{"issue":"60","key":"10.1016\/j.beha.2022.101378_bib24","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.18632\/oncotarget.21594","article-title":"Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria","volume":"8","author":"Rumi","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.beha.2022.101378_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.beha.2022.101378_bib26","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101378_bib27","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0596","article-title":"SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.beha.2022.101378_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.25294","article-title":"Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:22Z","timestamp":1761498442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692622000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1521692622000330"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2022.101378","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2022.101378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101378"}}